Clinical and Molecular Treatment of Gastrointestinal and Helicobacter pylori Disorders

Dear Colleagues,

Helicobacter pylori (H. pylori) is a major causative agent of chronic gastritis, gastric ulcers, and gastric carcinoma. H.-pylori-cytotoxin-associated antigen A (CagA) plays a crucial role in the development of gastric cancer. It is a gram negative, spiral-shaped, microaerophilic, and flagellated microorganism. More than 50% of the world population is colonized by H. pylori; however, only some people suffer from active disease depending on different factors such as age, gender, crowding, hyperacidity, smoking habit, and poor socioeconomic status. Developing countries have a high H. pylori prevalence rate of 80% compared with the rate in developed countries (20–50%). An epidemiological study in 1991 reported a link between H. pylori and gastric cancer and, in 1994, the World Health Organization (WHO) International Agency for Research on Cancer (IARC) classified H. pylori as a class I carcinogen (carcinogenic to humans).

Gastrointestinal cancers are among the highest death causing cancers in the world. The incidence of these cancers was an estimated 4.8 million cases and 3.4 million deaths worldwide. Gastrointestinal cancer is a group of cancers that affect the gastrointestinal tract. Gastrointestinal cancer includes esophageal, stomach, gallbladder, gastrointestinal stromal tumor, liver, pancreatic, colon, rectal, and anal cancers. Through this Special Issue, “Clinical and Molecular Treatment of Gastrointestinal and Helicobacter pylori Disorder”, we aim to highlight the new discoveries and advances in the mechanism, diagnosis, prevention, and treatment of gastrointestinal and Helicobacter pylori disorders.

We encourage contributions that are focused on, but are not limited to, the following themes:

• Lifestyle factors;
• Natural occurring exposures;
• Medical treatments;
• New drug treatment approaches for infection or inflammation or cancer;
• Dietary-associated treatment;
• Formation of advanced or combination treatment approaches for infection, inflammation, and cancers;
• Host‒pathogen interactions.

We are looking forward to your contributions.

Dr. Faisal Aziz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• gastrointestinal
• Helicobacter pylori
• dietary patterns
• infectious disease
• cancer
• precision medicine
• immune and targeted therapeutics
• radiotherapy
• cytotoxicity
• drugs
• clinical applications